Tasly Pharmaceuticals, Inc.

Quick facts

Marketed products

• Compound danshen dripping pills · Cardiovascular
  Compound danshen dripping pills improve blood circulation and reduce blood stasis by promoting vasodilation and inhibiting platelet aggregation.

Phase 3 pipeline

• 5LGr · Diabetes
  5LGr is a small molecule drug that targets the SGLT2 receptor.
• Sanqi+Bingpian · Cardiovascular
  Sanqi+Bingpian is a traditional Chinese medicine compound that has been studied for its potential anti-inflammatory and cardiovascular protective effects.
• T89 capsule · Cardiovascular
  T89 is a traditional Chinese medicine-derived compound that improves myocardial energy metabolism and enhances cardiac function through multiple pathways.
• T89 high dose · Cardiovascular
  T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease.
• T89 Low dose · Cardiovascular
  T89 is a traditional Chinese medicine compound that improves myocardial energy metabolism and reduces ischemic injury in cardiovascular disease.

Phase 2 pipeline

• Ginsenoside H dripping pills

Phase 1 pipeline

• T89 Group C
• Warfarin; Dantonic

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Tasly Pharmaceuticals, Inc. portfolio CI brief
• Tasly Pharmaceuticals, Inc. pipeline updates RSS